Recent Pfizer Press Releases

  • 9/29/14 8:00 pm EDT

    Agreement to Combine Kyowa Hakko Kirin’s Anti-CCR4 Antibody Mogamulizumab and Pfizer’s investigational 4-1BB agonist (PF-05082566) in Clinical Study

    NEW YORK & TOKYO--(BUSINESS WIRE)--
  • 9/25/14 8:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that it has completed its acquisition of the pharmaceutical development company, InnoPharma, Inc., following receipt of United States (U.S.) regulatory approval from all government authorities required by the agreement and other closing conditions. “We believe this acquisition will help Pfizer build a strong sterile injectables pipeline in areas such as oncology and central nervous disordersmore...
  • 9/23/14 10:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 28, 2014. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2014 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizermore...
  • 9/23/14 8:00 am EDT

    Pfizer launches new campaign to inspire postmenopausal women to tune into their bodies

    NEW YORK--(BUSINESS WIRE)--Every day, an estimated 6,000 women in the United States reach menopause.1 To inspire this growing population of women and to share her story, Golden Globe® winning actress Kim Cattrall has teamed up with Pfizer Inc. (NYSE:PFE), makers of prescription menopause treatments for certain menopausal symptoms, to launch the Tune In To Menopause™ (www.TuneInToMenopause.com) campaign which is designed to bring the conversation front and center andmore...
  • 9/19/14 8:00 am EDT
    • Efforts in support of the United Nations Millennium Development Goal (MDG) 4 to reduce under-5 child mortality rate.
    • Programs designed to reach children in remote locations in five African countries.
    NEW YORK--(BUSINESS WIRE)--The Pfizer Foundation today announced $2 million in grant funding for pilot programs to improve immunization coverage in Africa. The programs will focus on ‘last-mile’ interventions to reach underserved populations living in Ethiopia, Malawi, Rwanda, Uganda and Zambia. Grant recipients include UNICEF, Save the Children and International Rescue Committee. The grants will focus on building the capacity of health caremore...
  • 9/3/14 10:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Geno Germano, Group President, Global Innovative Pharma Business, at the Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2014 at 12:55 p.m. Eastern Daylight Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “Morgan Stanley Global Healthcare Conference” link in the For Investorsmore...
  • 8/28/14 1:15 pm EDT
    NEW YORK & CARMIEL, Israel--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Geno Germano, Group President, Global Innovative Pharma Business, at the Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2014 at 12:55 p.m. Eastern Daylight Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “Morgan Stanley Global Healthcare Conference” link in the For Investorsmore...
  • 8/28/14 8:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s investigational Clostridium difficile (C. difficile) vaccine candidate (PF-06425090). Currently in Phase 2 clinical development, the vaccine candidate is designed to prevent C. difficile-associated disease, which can include life-threatening diarrhea and pseudomembranous colitis. “C.more...
  • 8/26/14 8:00 am EDT

    Agreement to Combine Merck’s Investigational Anti-PD-1 Antibody Pembrolizumab and Pfizer’s Crizotinib (XALKORI®) in Clinical Trial

    NEW YORK & WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s investigational Clostridium difficile (C. difficile) vaccine candidate (PF-06425090). Currently in Phase 2 clinical development, the vaccine candidate is designed to prevent C. difficile-associated disease, which can include life-threatening diarrhea and pseudomembranous colitis. “C.more...
  • 8/21/14 1:31 pm EDT
    • Eliquis demonstrated noninferiority in the primary efficacy endpoint of recurrent symptomatic venous thromboembolism (VTE) or VTE-related death versus enoxaparin/warfarin in the AMPLIFY trial
    • Eliquis demonstrated superiority in the primary safety endpoint of major bleeding versus enoxaparin/warfarin in the AMPLIFY trial
    PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s investigational Clostridium difficile (C. difficile) vaccine candidate (PF-06425090). Currently in Phase 2 clinical development, the vaccine candidate is designed to prevent C. difficile-associated disease, which can include life-threatening diarrhea and pseudomembranous colitis. “C.more...